Patients with lung adenocarcinoma are classified based on molecular alterations of genes encoding kinases such as EGFR, KRAS, ALK, ROS1 and BRAF. 1,2 The presence of these alterations has led to clinical benefits for the subset of patients who can be effectively treated with targeted therapy. Here, ALK is linked to lung adenocarcinoma.